a broad research presentation by Amgen, aimed at our students, postdocs, and faculty. by their heads of Cardio Metabolic Resdearch (Aarif Khakoo) and Oncology and Inflammation Research (Martin Flavius). RH-102, 12pm, Mon Oct 31 cookies afterwards speaker bios: Dr. Aarif Khakoo, MD Dr. Aarif Khakoo is a physician scientist who is a Vice President, Research at Amgen leading the Cardiometabolic Disorders Discovery Research Group. Dr. Khakoo received his BSE from Princeton University and his MD and MBA from Columbia University. He performed residency training and a fellowship in Cardiovascular Medicine at the Johns Hopkins University School of Medicine. His postdoctoral training at the National Heart, Lung and Blood Institute focused on studying the interaction of adult stem cells with tumor cells. Prior to joining Amgen, Dr. Khakoo was an Associate Professor at The University of Texas MD Anderson Cancer Center, leading a laboratory focused on studying the mechanisms of cardiovascular toxicity of targeted cancer therapeutics. In his current role, Dr. Khakoo’s group focuses seeks to discover and develop novel therapeutics for heart failure, atherosclerosis, obesity/metabolic syndrome, and other cardiovascular diseases. Dr. Khakoo continues to be active clinically as an Adjunct Associate Clinical Professor at the Stanford University School of Medicine. Flavius Martin, MD Dr Flavius Martin, Vice President, Discovery Research joined Amgen in 2013 and is heading the Inflammation and Oncology departments. Prior to that dr Martin spent 11 years at Genentech, where he directed a portfolio of programs focused on drug discovery in autoimmune and allergic disorders. Dr. Martin received his MD from the University of Medicine and Pharmacy in Timisoara, Romania and did his postdoctoral work in the center of developmental and clinical immunology in Birmingham, Alabama, USA. Dr. Martin published work focuses on the development and functions of B lymphocytes, next-generation immunotherapies, and the molecular mechanisms that underlie human myeloproliferative syndromes.